Showing results (1-10 of 262) with videos related to
Sort By:
Pageof 27
Annals of the Rheumatic Diseases|January 23, 2023
Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosusEric F Morand, Gabriel Abreu, Richard A Furie, et al.Rheumatology (Oxford, England)|September 16, 2021
Relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with systemic lupus erythematosusYen Lin Chia, Jianchun Zhang, Raj Tummala, et al.Lupus Science & Medicine|February 18, 2021
Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trialsRaj Tummala, Gabriel Abreu, Lilia Pineda, et al.The Lancet. Rheumatology|January 30, 2024
Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trialsEric F Morand, Richard A Furie, Ian N Bruce, et al.The Lancet. Rheumatology|January 30, 2024
Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a post-hoc analysis of the phase 3 TULIP-1 and TULIP-2 trials of anifrolumabVibeke Strand, Sean O'Quinn, Richard A Furie, et al.Journal of Clinical Pharmacology|March 30, 2022
Relationship Between Anifrolumab Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Moderate to Severe Systemic Lupus ErythematosusYen Lin Chia, Raj Tummala, Tu H Mai, et al.Rheumatology (Oxford, England)|August 26, 2022
Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: a post hoc analysis of the TULIP-1 and TULIP-2 trialsIan N Bruce, Ronald F van Vollenhoven, Eric F Morand, et al.Current Opinion in Rheumatology|April 7, 2007
Effects of glucocorticoids on inflammation and arthritisEric F MorandAnnals of the Rheumatic Diseases|February 13, 2025
LLDAS and remission attainment with anifrolumab treatment in patients with systemic lupus erythematosus: results from the TULIP and long-term extension randomised controlled trialsEric F Morand, Ronald van Vollenhoven, Richard A Furie, et al.Internal Medicine Journal|August 23, 2021
Systemic lupus erythematosus: a clinical updateKathryn Connelly, Eric F MorandPageof 27